
    
      This study is being conducted to establish bioequivalence between sponsor's test product
      [fulvestrant Injection, 50 mg/mL (Manufactured for Fresenius Kabi, USA)] and reference listed
      drug [FaslodexÂ® Injection, 50 mg/mL, (Distributed by AstraZeneca Pharmaceuticals, USA] after
      intramuscular administration of a 250 mg dose (5 mL injection) into the upper outer quadrant
      of the right buttock to normal, healthy, nonsmoking post-menopausal female subjects.

      The order of receiving the test product (T) or reference listed drug (R) for each subject
      during the study will be determined according to a randomization schedule.

      Subjects will be allocated with a ratio of 1:1 to both treatment groups (i.e. T and R).
    
  